Medplus Health Services Limited (MEDPLUS) has announced its Q2 FY2027 results, showcasing a robust performance in the quarter. The company reported a revenue of ₹20,371 million, marking a significant 21.3% year-over-year increase. The gross margin stood at 25.1%, reflecting a slight decline of 110 basis points year-over-year but a 60 basis points improvement quarter-over-quarter.

Revenue and Growth

The revenue for Q2 FY2027 was ₹20,371 million, which is ₹3,578 million higher than the same period last year. This growth is complemented by a quarter-over-quarter increase of ₹1,575 million, representing an 8.4% rise. The company also experienced a 0.6% decrease in private label revenue compared to Q2 FY26.

Store Expansion and Profitability

MEDPLUS added 166 new stores in Q2 FY2027, bringing the total store count to 5,642. Of these, 101 were net additions beyond Tier-One cities. The company’s store-level EBITDA margin improved to 11.7%, and the operating ROCE (Return on Capital Employed) stood at 72.0%.

Financial Performance

The pharmacy operating EBITDA for the quarter was ₹885 million, showing a 4.4% operating EBITDA margin, up by 120 basis points quarter-over-quarter. The company’s consolidated operating EBITDA reached ₹981 million, and the operating cash flow was ₹370 million, resulting in a 37.7% ratio of operating cash flow to operating EBITDA.

As a forward-looking statement, MEDPLUS remains optimistic about its growth trajectory, leveraging its extensive network of 5,642 stores across 13 states and 1 union territory. The company aims to further penetrate existing clusters and develop new ones, capitalize on its omni-channel strategy, and expand its private label offerings to drive higher margins and customer retention.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Medplus Health Services Limited

Medplus Health Services Limited belongs to the Healthcare › Pharmaceutical Retailers sector. Here’s a quick read on where the business and the stock stand today.

Medplus drops 23.6% over three months and trades near its 52-week lows. The PEG of 0.55 signals undervaluation relative to growth. It is a potential re-rating candidate. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. RSI stands at 26, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. The business compounds at 14.7% revenue and 64.0% profit CAGR, with D/E of 0.64. Yet the stock drops 23.6% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Medplus Health Services Limited.

Mankind Pharma Limited (MANKIND) is set to host an Analyst/Investor Meet on October 2026, providing insights into its growth trajectory and strategic initiatives. The company, which has consistently demonstrated robust performance, will focus on its expansion in chronic and specialty divisions, hospital business, and consumer healthcare segments. With a revenue of ₹14,278 Cr in FY26, the company has shown an 18.1% Revenue CAGR from FY21 to FY26, underscoring its market leadership.

Growth Revival and Strategic Initiatives

The meet will highlight Mankind Pharma’s growth revival through its eight pillars of growth, including scaling branded specialty ACTx, expanding its hospital business, and focusing on good-to-great brands. The company has also made significant strides in consumer healthcare, becoming a leader in sexual wellness and expanding into consumer wellness with brands like Gas-O-Fast and Acne Star.

Future Outlook

Looking ahead, Mankind Pharma aims to deepen its penetration in high-barrier specialty brands and geographical expansion of key products in emerging markets. With a focus on high revenue growth and innovative bets, the company is poised to continue its impressive growth trajectory.

As a result of these strategic initiatives, Mankind Pharma is well-positioned to achieve its goal of becoming a global leader in pharmaceuticals.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Mankind Pharma Limited

Mankind Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Mankind falls 8.4% over three months and has not found a floor yet. The PEG reaches 3.22. The stock trades on brand and index weight, not on growth. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gains 1.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 17.7% and profits at 14.3% CAGR, with D/E of 0.58. Meanwhile, the stock dips 8.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Mankind Pharma Limited.

Indoco Remedies Limited (NSE: INDOCO) has announced that its Clinical Research Organisation, AnaCipher, has received approval from the National Health Surveillance Agency of Brazil (ANVISA) for both clinical and bioanalytical facilities. This approval, granted after an inspection conducted from March 30 to April 7, 2026, authorizes AnaCipher to conduct Bioavailability & Bioequivalence studies for submission to Brazil, along with associated bioanalytical support in accordance with ANVISA regulatory requirements.

Significance of the Approval

Commenting on this development, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “The approval reflects our CRO’s robust quality management systems, qualified scientific and clinical teams, validated analytical capabilities, and adherence to international regulatory and Good Clinical Practice standards. It reinforces our commitment to global quality standards and enhances our ability to support pharmaceutical companies in conducting studies for Brazil and expanding across Latin America.”

Strengthening Global Footprint

This approval further strengthens AnaCipher’s international regulatory footprint and reinforces its position as a trusted partner for global clinical research programmes. AnaCipher, headquartered in Hyderabad, India, provides bioequivalence and bioavailability studies, bioanalysis, clinical operations, regulatory affairs, data management, and biostatistics services to pharmaceutical companies worldwide. The CRO has been accredited by CDSCO, USFDA, WHO, EMA, UKMHRA, MoH -Oman, TPD -Canada, NMPA – China, MCC -South Africa, and MoH -Iraq.

As a fully integrated, research-oriented pharmaceutical company, Indoco Remedies Limited has a strong global presence with a turnover of US$ 175 million and a workforce of over 6000 employees, including over 300 skilled scientists and field staff. The company has 10 manufacturing facilities, supported by a state-of-the-art R&D Centre and a CRO facility, and its facilities have been approved by most regulatory authorities including USFDA and UK-MHRA.

For more details, visit www.anaciphercro.com and www.indoco.com.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indoco Remedies Limited

Indoco Remedies Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Indoco holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at only 3.0% and profits at 0.0% CAGR. In effect, the business treads water. The stock holds at 64% of its 52-week range with RSI at 51. In other words, neither side has a clear edge right now. The stock holds up despite 3.0% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Indoco Remedies Limited.